Exhibit
10.1


 


Execution
Version


 


PURCHASE
AGREEMENT


 


PURCHASE
AGREEMENT (the “Agreement”), dated as of May 2, 2018, by and between AURIS MEDICAL HOLDING AG, a
company established in Switzerland (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois
limited liability company (the “Investor”).


 


WHEREAS:



 


Subject
to the terms and conditions set forth in this Agreement, the Company wishes to issue to the Investor, and the Investor wishes
to subscribe for, up to Ten Million Dollars ($10,000,000) of the Company's Common Shares (as defined below). The Common Shares
to be issued to the Investor hereunder are referred to herein as the "Purchase Shares."


 


NOW
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:


 


1.       CERTAIN
DEFINITIONS. 


 


For
purposes of this Agreement, the following terms shall have the following meanings:


 


(a)       “Additional
Purchase Notice” means, with respect to any Additional Purchase pursuant to Section 2(b) hereof, an irrevocable
written notice from the Company to the Investor directing the Investor to buy such applicable amount of Purchase Shares at the
applicable Additional Purchase Price as specified by the Company therein on the Purchase Date.


 


(b)       “Additional
Purchase Price” means, with respect to any Additional Purchase made pursuant to Section 2(b) hereof, the lower
of: (i) $5.00 per share and (ii) ninety-six percent (96%) of the Purchase Price (as defined below) (in each case, to be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on
or after the date of this Agreement).


 


(c)       “Alternate
Adjusted Regular Purchase Share Limit” means, with respect to a Regular Purchase made pursuant to Section 2(a)
hereof, the maximum number of Purchase Shares which, taking into account the applicable Purchase Price therefor on the applicable
Purchase Date for the applicable Regular Purchase Notice, would enable the Company to effect a Regular Purchase for a Purchase
Amount equal to, or as closely approximating without exceeding, One Hundred Thousand Dollars ($100,000)).


 


(d)
      “Available Amount” means, initially, Ten Million Dollars ($10,000,000)
in the aggregate, which amount shall be reduced by the Purchase Amount each time the Investor purchases Common Shares pursuant
to Section 2 hereof.


 


(e)       “Bankruptcy
Law” means Title 11, U.S. Code, or any similar U.S. federal or state law or Swiss law for the relief of debtors.


 




     


     


    

(f)       “Business
Day” means any day on which commercial banks in Berne, Switzerland and Basel, Switzerland are open for regular business
and the Principal Market is open for trading, including any day on which the Principal Market is open for trading for a period
of time less than the customary time.


 


(g)       “Closing
Sale Price” means, for any security as of any date, the last closing sale price for such security on the Principal Market
as reported by the Principal Market.


 


(h)       “Common
Shares” means the Company’s common shares, with a nominal value CHF 0.02 per share (as may be adjusted) or the
common shares of any successor of the Company resulting from any reorganization transaction.


 


(i)       “Confidential
Information” means any information disclosed by either party to the other party, either directly or indirectly, in writing,
orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment),
which is designated as "Confidential," "Proprietary" or some similar designation. Information communicated
orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information
within ten (10) Business Days after the initial disclosure. Confidential Information shall not, however, include any information
which (i) was publicly known and made generally available in the public domain prior to the time of disclosure by the disclosing
party; (ii) becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party
through no action or inaction of the receiving party; (iii) is already in the possession of the receiving party at the time of
disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior to the time of
disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party’s obligations
of confidentiality; (v) is independently developed by the receiving party without use of or reference to the disclosing party’s
Confidential Information, as shown by documents and other competent evidence in the receiving party’s possession; or (vi)
is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt
written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from
public disclosure.


 


(j)       “Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.


 


(k)       “DTC”
means The Depository Trust Company, or any successor performing substantially the same function for the Company.


 


(l)        “DWAC
Shares” means Common Shares that are (i) issued in electronic form, (ii) freely tradable and transferable and without
restriction on resale (subject to any applicable restrictions set forth in the articles of association of the Company) and (iii)
timely credited by the Company to the Investor’s or its designee’s specified Deposit/Withdrawal at Custodian (DWAC)
account with DTC under its Fast Automated Securities Transfer (FAST) Program or any similar program hereafter adopted by DTC performing
substantially the same function.


 


(m)
     “Exchange Act” means the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder.


 


(n)
     “Exchange Rate” means, in relation to any amount of currency to be
converted into U.S. Dollars pursuant to this Agreement, the U.S. Dollar exchange rate as published in the Wall Street Journal
on the relevant date of calculation.


 




    -2-


     


    

(o)       “Floor
Price” means $0.25, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction after the date hereof and, effective upon the consummation of any such reorganization,
recapitalization, non-cash dividend, stock split or other similar transaction, the “Floor Price” shall mean the greater
of (i) the lower of (A) the U.S. Dollar adjusted price as a result of such transaction and (B) $0.50, and (ii) the U.S. Dollar
equivalent of the then applicable nominal value of a single Common Share, giving effect to any adjustment thereto as a result
of such transaction, calculated in accordance with the applicable Exchange Rate on such relevant date of determination.


 


(p)       “Fully
Adjusted Regular Purchase Share Limit” means, with respect to any reorganization, recapitalization, non-cash dividend,
stock split or other similar transaction from and after the date of this Agreement, the Regular Purchase Share Limit (as defined
in Section 2(a) hereof) in effect on the applicable date of determination, after giving effect to the full proportionate
adjustment thereto made pursuant to Section 2(a) hereof for or in respect of such reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction.


 


(q)       “Issue
Price” means the U.S. Dollar equivalent of the applicable nominal value of a single Common Share (which, as of the date
of this Agreement, is CHF 0.02) as of the relevant date of determination, calculated in accordance with the applicable Exchange
Rate on such relevant date of determination; provided, however, that irrespective of any Exchange Ratio, the amount
per Common Share to be effectively credited to the Capital Increase Account (as defined herein) as further set forth in this Agreement
must in any case be a Swiss franc denominated amount not lower than the applicable nominal value of a single Common Share as of
the relevant date of determination.


 


(r)       “Material
Adverse Effect” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the
condition (financial or other), earnings, business, properties, operations, assets, liabilities or prospects of the Company and
its Subsidiaries, considered as one entity, or (iii) the Company’s ability to perform in any material respect on a
timely basis its obligations under any Transaction Document to be performed as of the date of determination.


 


(s)       “Maturity
Date” means the first day of the month immediately following the thirty (30) month anniversary of the Commencement Date.


 


(t)       “PEA
Period” means the period commencing at 9:30 a.m., Eastern time, on the fifth (5th) Business Day immediately
prior to the filing of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement
(as such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the Business Day immediately
following, the effective date of any post-effective amendment to the Registration Statement (as defined herein) or New Registration
Statement (as such term is defined in the Registration Rights Agreement).


 


(u)       “Person”
means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization and a government or any department or agency thereof.


 


(v)       “Principal
Market” means The NASDAQ Capital Market (or any nationally recognized successor thereto); provided, however,
that in the event the Common Shares are ever listed or traded on The NASDAQ Global Market, The NASDAQ Global Select Market, the
New York Stock Exchange, the NYSE American, the NYSE Arca or the OTC Bulletin Board (it being understood that as used herein “OTC
Bulletin Board” shall also mean any successor or comparable market quotation system or exchange to the OTC Bulletin Board
such as the OTCQX and OTCQB operated by the OTC Markets Group, Inc.),


 




    -3-


     


    

then
the “Principal Market” shall mean such other market or exchange on which the Common Shares are then listed or traded
or any successor thereto.


 


(w)       “Purchase
Amount” means, with respect to any Regular Purchase or any Additional Purchase made hereunder, as applicable, the portion
of the Available Amount to be purchased by the Investor pursuant to Section 2 hereof.


 


(x)       “Purchase
Date” means, (i) with respect to any Regular Purchase made pursuant to Section 2(a) hereof, the Business Day
on which the Investor receives after 4:00 p.m., Eastern time, but prior to 5:00 p.m., Eastern time, of such Business Day a valid
Regular Purchase Notice that the Investor is to buy Purchase Shares pursuant to Section 2(a) hereof, or (ii) with respect
to any Additional Purchase made pursuant to Section 2(b) hereof, the Business Day on which the Investor receives after
4:00 p.m., Eastern time, but prior to 5:00 p.m., Eastern time, of such Business Day a valid Additional Purchase Notice that the
Investor is to buy Purchase Shares pursuant to Section 2(b) hereof, as applicable.


 


(y)       “Purchase
Price” means, with respect to any Regular Purchase made pursuant to Section 2(a) hereof or any Additional Purchase
made pursuant to Section 2(b) hereof (as applicable), the lower of: (i) the lowest Sale Price on the applicable Purchase
Date and (ii) the arithmetic average of the three (3) lowest Closing Sale Prices for the Common Shares during the ten (10) consecutive
Business Days ending on the Business Day immediately preceding such Purchase Date (in each case, to be appropriately adjusted
for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after
the date of this Agreement).


 


(z)       “Regular
Purchase Notice” means, with respect to any Regular Purchase pursuant to Section 2(a) hereof, an irrevocable
written notice from the Company to the Investor directing the Investor to buy such applicable amount of Purchase Shares at the
applicable Purchase Price as specified by the Company therein on the Purchase Date.


 


(aa)       “Sale
Price” means any trade price for the Common Shares on the Principal Market as reported by the Principal Market.


 


(bb)       “SEC”
means the U.S. Securities and Exchange Commission.


 


(cc)“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


(dd)“Subsidiary”
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the
voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K
promulgated under the Securities Act.


 


(ee)“Transaction
Documents” means, collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement
and the schedules and exhibits thereto, and each of the other documents, certificates and instruments entered into or furnished
by the parties hereto in connection with the transactions contemplated hereby and thereby.


 


(ff)“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, or such other Person who is then serving as the transfer
agent for the Company in respect of the Common Shares.


 


2.
PURCHASES. 


 




    -4-


     


    

Subject
to the terms and conditions set forth in this Agreement, the Company has the right to issue to the Investor, and the Investor
has the obligation to subscribe for, Purchase Shares as follows:


 


(a)       Commencement
of Regular Purchases. Upon the satisfaction of all of the conditions set forth in Sections 7 and 8 hereof (the
“Commencement” and the date of satisfaction of such conditions the “Commencement Date”)
and thereafter, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the Investor
of a Regular Purchase Notice from time to time, to purchase up to Two Hundred Fifty Thousand (250,000) Purchase Shares, subject
to adjustment as set forth below in this Section 2(a) (such maximum number of Purchase Shares, as may be adjusted from
time to time, the “Regular Purchase Share Limit”), at the Purchase Price on the Purchase Date (each such purchase
a “Regular Purchase”); provided, however, that (i) the Regular Purchase Share Limit shall be
increased to Three Hundred Thousand (300,000) Purchase Shares, if the total number of outstanding Common Shares on the applicable
Purchase Date exceeds Ten Million (10,000,000) Common Shares, (ii) the Regular Purchase Share Limit shall be increased to Three
Hundred Fifty Thousand (350,000) Purchase Shares, if (A) the Closing Sale Price of the Common Shares on the applicable Purchase
Date is not below $1.00 and (B) the total number of outstanding Common Shares on the applicable Purchase Date exceeds Twelve Million
Five Hundred Thousand (12,500,000) Common Shares, and (iii) the Regular Purchase Share Limit shall be increased to Four Hundred
Thousand (400,000) Purchase Shares, if (A) the Closing Sale Price of the Common Shares on the applicable Purchase Date is not
below $1.00 and (B) the total number of outstanding Common Shares on the applicable Purchase Date exceeds Fifteen Million (15,000,000)
Common Shares (all of which share and dollar amounts shall be appropriately proportionately adjusted for any reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction; provided that if, after giving effect to the full proportionate adjustment
to the Regular Purchase Share Limit therefor, the Fully Adjusted Regular Purchase Share Limit then in effect would preclude the
Company from delivering to the Investor a Regular Purchase Notice hereunder for a Purchase Amount (calculated by multiplying (X)
the number of Purchase Shares equal to the Fully Adjusted Regular Purchase Share Limit, by (Y) the Purchase Price per Purchase
Share covered by such Regular Purchase Notice on the applicable Purchase Date therefor) equal to or greater than One Hundred Thousand
Dollars ($100,000), the Regular Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted to equal the
applicable Fully Adjusted Regular Purchase Share Limit, but rather the Regular Purchase Share Limit for such Regular Purchase
Notice shall be adjusted to equal the applicable Alternate Adjusted Regular Purchase Share Limit as of the applicable Purchase
Date for such Regular Purchase Notice; and provided, further, however, that the Investor’s committed
obligation under any single Regular Purchase, other than any Regular Purchase with respect to which an Alternate Adjusted Regular
Purchase Share Limit shall apply, shall not exceed One Million Dollars ($1,000,000). If the Company delivers any Regular Purchase
Notice for a Purchase Amount in excess of the limitations contained in the immediately preceding sentence, such Regular Purchase
Notice shall be void ab initio to the extent of the amount by which the number of Purchase Shares set forth in such Regular
Purchase Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance
herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Regular Purchase
Notice; provided, however, that the Investor shall remain obligated to purchase the number of Purchase Shares which
the Company is permitted to include in such Regular Purchase Notice. The Company may deliver a Regular Purchase Notice to the
Investor only if at least one (1) Business Day has passed since the Closing Date on which the most recent Regular Purchase was
completed in accordance with this Agreement. Notwithstanding the foregoing, (i) the Company may not deliver a Regular Purchase
Notice to the Investor, and the Investor and the Company shall not effect any Regular Purchase under this Agreement, on any Purchase
Date that the Closing Sale Price of the Common Shares is less than the Floor Price and (ii) the Company shall not deliver any
Regular Purchase Notices to the Investor during the PEA Period.


 




    -5-


     


    

(b)       Additional
Purchases. Subject to the terms and conditions of this Agreement, from and after the Commencement Date, in addition to purchases
of Purchase Shares as described in Section 2(a) above, the Company shall also have the right, but not the obligation, to
direct the Investor by the Company’s delivery to the Investor of an Additional Purchase Notice from time to time, and the
Investor thereupon shall have the obligation, to buy Purchase Shares at the Additional Purchase Price on the Purchase Date (each
such purchase, an “Additional Purchase”); provided, however, that (i) the Company may deliver
an Additional Purchase Notice to the Investor only if at least fifteen (15) Business Days have passed since the Closing Date on
which the most recent Additional Purchase was completed in accordance with this Agreement, (ii) the Company shall not direct the
Investor to purchase in any single Additional Purchase a number of Purchase Shares for which the aggregate Additional Purchase
Price therefor, as calculated in accordance with this Agreement on the applicable Purchase Date, is less than One Hundred Thousand
Dollars ($100,000), (iii) the Investor’s committed obligation under any single Additional Purchase shall not exceed Five
Hundred Thousand Dollars ($500,000), and (iv) the Investor’s committed obligation under all Additional Purchases shall not
exceed Two Million Dollars ($2,000,000) in the aggregate. The Company may deliver an Additional Purchase Notice to the Investor
only on a Purchase Date on which (A) the Closing Sale Price of the Common Shares is not below $1.00 (to be appropriately adjusted
for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) and (B) the total number
of outstanding Common Shares exceeds Twelve Million Five Hundred Thousand (12,500,000) Common Shares (to be appropriately adjusted
for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction). If the Company: (I) delivers
any Additional Purchase Notice for a Purchase Amount that is less than minimum amount required for any single Additional Purchase
pursuant to clause (ii) of the proviso of the first sentence of this Section 2(b), such Additional Purchase Notice shall
be void ab initio and the Investor shall not purchase any Purchase Shares included in such Additional Purchase Notice,
or (II) delivers any Additional Purchase Notice for a Purchase Amount in excess of the limitations contained in this Section
2(b) (excluding clause (ii) of the proviso of the first sentence of this Section 2(b)), such Additional Purchase Notice
shall be void ab initio to the extent of the amount by which the number of Purchase Shares set forth in such Additional
Purchase Notice exceeds the number of Purchase Shares which the Company is permitted to include in such Additional Purchase Notice
in accordance herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Additional
Purchase Notice; provided that with respect to this clause (II), the Investor shall remain obligated to purchase the number of
Purchase Shares which the Company is permitted to include in such Additional Purchase Notice. Notwithstanding the foregoing, the
Company shall not deliver any Additional Purchase Notice during the PEA Period.


 


(c)       
Payment for Purchase Shares.


 


(i)
Payment of Capital Increase Amount. Not later than (A) 10:30 a.m., Eastern Time, on the Commencement Date, the Investor
shall deposit or cause to be deposited same-day funds for value in an amount equal to (1) the Issue Price as of the Business Day
immediately preceding the Commencement Date, multiplied by (2) the maximum total number of Purchase Shares, calculated by reference
to the Closing Sale Price of the Common Shares on the Business Day immediately preceding the Commencement Date (assuming such
Business Day was the Purchase Date for such Regular Purchase), that may become the subject of the first Regular Purchase Notice
that may be delivered by the Company hereunder (which aggregate amount shall be denominated in Swiss francs and correspond to
the aggregate nominal value for such Purchase Shares as of the Business Day immediately preceding the Commencement Date), and
(B) the later of (1) 10:30 a.m., Eastern Time, on the Commencement Date and (2) 10:30 a.m., Eastern Time, on the next Business
Day immediately following the date on which the Investor shall have received written confirmation from the Company that the total
number of then outstanding Common Shares exceeds Twelve Million Five Hundred Thousand (12,500,000) Common Shares (to be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock


 




    -6-


     


    

split or
other similar transaction) (such later date, the “Additional Purchase Initial Deposit Date”), the Investor
shall deposit or cause to be deposited same-day funds for value in an aggregate amount equal to (I) the Issue Price as of the
Business Day immediately preceding the Additional Purchase Initial Deposit Date, multiplied by (II) the maximum total number of
Purchase Shares, based on an assumed Additional Purchase Price for such Purchase Shares calculated as of the Business Day immediately
preceding the Additional Purchase Initial Deposit Date (assuming such Business Day was the Purchase Date for such Additional Purchase),
that may become the subject of the first Additional Purchase Notice that may be delivered by the Company hereunder (which aggregate
amount shall be denominated in Swiss francs and correspond to the aggregate nominal value for such Purchase Shares as of the Business
Day immediately preceding the Additional Purchase Initial Deposit Date) (the amount of any such deposit of the aggregate nominal
value of Purchase Shares made in accordance with this Section 2(c)(i) hereinafter referred to as a “Capital Increase
Amount”) in the Capital Increase Account (as defined below) maintained at the Capital Increase Bank (as defined below),
and each of the Investor and the Company shall take all actions reasonably necessary to cause the Capital Increase Bank to issue
and deliver the original of a written confirmation of payment of such Capital Increase Amount to the Company not later than 11:00
a.m. (CEST) on the first (1st) Business Day immediately following the date on which such Capital Increase Amount was
deposited by the Investor hereunder. On the first (1st) Business Day immediately following each Closing Date on which
a Regular Purchase was completed in accordance with this Agreement (including the receipt by the Investor of all Purchase Shares
subject thereto in accordance with this Agreement), the Investor shall deposit or cause to be deposited same-day funds for value
in an aggregate amount equal to (1) the Issue Price as of the applicable Regular Purchase Capital Increase Reference Date (as
defined below) multiplied by (2) the maximum total number of Purchase Shares, calculated by reference to the Closing Sale Price
of the Common Shares on such immediately preceding Closing Date (assuming such Closing Date was the Purchase Date therefor) (such
immediately preceding Closing Date referenced for such calculation, a “Regular Purchase Capital Increase Reference Date”),
that may become the subject of the next subsequent Regular Purchase Notice that may be delivered by the Company hereunder (which
aggregate amount shall be denominated in Swiss francs and correspond to the aggregate nominal value for such Purchase Shares as
of such Regular Purchase Capital Increase Reference Date and shall be the relevant Capital Increase Amount) in the Capital Increase
Account maintained at the Capital Increase Bank, and each of the Investor and the Company shall take all actions reasonably necessary
to cause the Capital Increase Bank to issue and deliver the original of a written confirmation of payment of such Capital Increase
Amount to the Company not later than 11:00 a.m. (CEST) on the first (1st) Business Day immediately following the Business
Day on which such Capital Increase Amount was deposited. On any Business Day on or after the tenth (10th) Business
Day immediately following a Closing Date on which an Additional Purchase was completed in accordance with this Agreement (including
the receipt by the Investor of all Purchase Shares subject thereto in accordance with this Agreement), the Company may deliver
a written request to the Investor, in accordance with Section 12(f) hereof, to deposit the applicable Capital Increase
Amount to be used in connection with the next subsequent Additional Purchase, if any. Not later than 10:30 a.m., Eastern Time,
on the first (1st) Business Day immediately following the date on which the Investor received the written request of
the Company referred to in the immediately preceding sentence, the Investor shall deposit or cause to be deposited the applicable
Capital Increase Amount in same-day funds for value in an aggregate amount equal to (I) the Issue Price as of the Additional Purchase
Capital Increase Reference Date (as defined below) multiplied by (II) the maximum total number of Purchase Shares, based on an
assumed Additional Purchase Price for such Purchase Shares calculated as of the Business Day immediately preceding the Business
Day on which such funds are to be deposited hereunder (assuming such Business Day was the Purchase Date therefor) (each such Business
Day referenced for such calculation, an “Additional Purchase Capital Increase Reference Date”), that may become
the subject of the next subsequent Additional Purchase Notice that may be delivered by the Company hereunder (which aggregate
amount shall be denominated in Swiss francs and shall correspond to the aggregate nominal value for such Purchase Shares as of
such Additional Purchase Capital Increase Reference Date and shall be the applicable Capital Increase Amount) in the Capital Increase
Account


 




    -7-


     


    

maintained
at the Capital Increase Bank, and each of the Investor and the Company shall take all actions reasonably necessary to cause the
Capital Increase Bank to issue and deliver the original of a written confirmation of payment of such Capital Increase Amount to
the Company not later than 11:00 a.m. (CEST) on the first (1st) Business Day immediately following the Business Day
on which such Capital Increase Amount was deposited. For the avoidance of doubt, (i) if, as of any Regular Purchase Capital Increase
Reference Date, the Company would not be eligible to deliver a Regular Purchase Notice to the Investor (assuming such Regular
Purchase Capital Reference Date was the Purchase Date therefor) under the terms of this Agreement, the Investor’s obligation
to deposit any Capital Increase Amount under this Agreement in respect of a future Regular Purchase under this Section 2(c)(i)
shall be tolled until the first Business Day on which the Company is then permitted to deliver a Regular Purchase Notice to
the Investor under the terms of this Agreement, upon which the Investor shall deposit or cause to be deposited on the next Business
Day the applicable total Capital Increase Amount with respect to a future Regular Purchase Notice pursuant to this this Section
2(c)(i) (assuming such first Business Day on which the Company is then permitted to deliver a Regular Purchase Notice to the
Investor under the terms of this Agreement was the Purchase Date therefor), and (ii) if, as of any Additional Purchase Capital
Increase Reference Date, the Company would not be eligible to deliver an Additional Purchase Notice to the Investor (assuming
such Additional Purchase Capital Reference Date was the Purchase Date therefor) under the terms of this Agreement, the Investor’s
obligation to deposit any Capital Increase Amount under this Agreement in respect of a future Additional Purchase under this Section
2(c)(i) shall be tolled until the first Business Day on which the Company is then permitted to deliver an Additional Purchase
Notice to the Investor under the terms of this Agreement, upon which the Investor shall deposit or cause to be deposited on the
next following Business Day the applicable total Capital Increase Amount with respect to a future Additional Purchase Notice pursuant
to this Section 2(c)(i) (assuming such first Business Day on which the Company is then permitted to deliver an Additional
Purchase Notice to the Investor under the terms of this Agreement is the Purchase Date therefor).


 


(ii)
Payment of Purchase Amount Balance. On the first (1st) Business Day following the applicable Purchase Date for
a Regular Purchase, and on the first (1st) Business Day following the applicable Purchase Date for an Additional Purchase,
as applicable, the Investor shall deduct the U.S. Dollar equivalent of the applicable total Capital Increase Amount, calculated
using the same Exchange Rate used by the Investor to procure such Capital Increase Amount pursuant to Section 2(c)(i),
from the applicable Purchase Amount that the Investor is required to pay in such Regular Purchase and/or Additional Purchase,
respectively, for the same number of Purchase Shares for which the applicable total Capital Increase Amount was deposited pursuant
to Section 2(c)(i) (such amount herein referred to as a “Purchase Amount Balance”), and, not later than
10:30 a.m., Eastern Time, on such Business Day, the Investor shall release a wire transfer of immediately available funds (to
be credited to the General Account with the General Account Bank) in the amount of the applicable total Purchase Amount Balance
which, together with the applicable total Capital Increase Amount, shall equal the total applicable Purchase Amount that the Investor
is required to pay for such Purchase Shares in such Regular Purchase and/or Additional Purchase, respectively. Not later than
1:00 p.m., Eastern Time, on the second (2nd) Business Day following the applicable Purchase Date for a Regular Purchase,
and not later than 1:00 p.m., Eastern Time, on the second (2nd) Business Day following the applicable Purchase Date
for an Additional Purchase, as applicable (each such Business Day, a “Closing Date”), provided that the applicable
total Purchase Amount with respect thereto shall have been deposited by the Investor in accordance with this Section 2(c)
(and, for the avoidance of doubt, in any case prior to the resolution to be taken as set forth in Section 2(g)), the Company
shall deliver, or cause to be delivered to the Investor, all of the Purchase Shares to be purchased by the Investor in connection
with such Regular Purchase and/or Additional Purchase, respectively, as DWAC Shares. The Purchase Shares to be purchased by the
Investor in connection with any Regular Purchase and/or Additional Purchase, as applicable, shall be registered in such names
and denominations as the Investor shall have requested prior to the applicable Closing Date. The Company agrees that if the Company
or the Transfer Agent defaults in its obligation to


 




    -8-


     


    

timely deliver
all or any of the Purchase Shares as DWAC Shares on the applicable Closing Date in accordance with this Section 2(c)(ii)
(other than as a result of the Investor or its broker failing to send an electronic request to the Transfer Agent requesting that
the Purchase Shares be delivered to the Investor's or its designee's specified DWAC account with DTC under its FAST Program or
any similar program hereafter adopted by DTC performing substantially the same function), and if after such date the Investor
is required by its broker to purchase or the Investor’s brokerage firm otherwise purchases Common Shares to deliver in satisfaction
of a sale of such Purchase Shares that the Investor anticipated receiving from the Company in respect of such Regular Purchase
or Additional Purchase (as applicable), then the Company shall, within three (3) Business Days after the Investor’s request,
either (A) pay cash to the Investor in an amount equal to the Investor’s total purchase price (including brokerage commissions,
if any) for the Common Shares so purchased (the “Cover Price”), at which point the Company’s obligation
to deliver such Purchase Shares as DWAC Shares shall terminate, or (B) promptly honor its obligation to deliver to the Investor
such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the Cover Price
over the total Purchase Amount paid by the Investor pursuant to this Agreement for all of the Purchase Shares to be purchased
by the Investor in connection with such Regular Purchase and/or Additional Purchase, as applicable. The Company shall not issue
any fraction of a Common Share upon any Regular Purchase or Additional Purchase. If the issuance would result in the issuance
of a fraction of a Common Share, the Company shall round such fraction of a Common Share up or down to the nearest whole share.
All payments made under this Agreement shall be made in lawful money of the United States of America or wire transfer of immediately
available funds to such account as the Company may from time to time designate by written notice in accordance with the provisions
of this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business
Day, the same shall instead be due on the next succeeding day that is a Business Day.


 


(d)       Shareholder’s
Resolution on Capital Increase. The Company confirms that:


 


(i)       pursuant
to the articles of association, the Board of Directors of the Company (the “Board”) may effect an increase
of the Company’s share capital in a maximum amount of CHF 61,000.00 by issuing up to 3,050,000 Common Shares out of the
Company’s authorized share capital, such authorization having been granted by resolution of the shareholders meeting of
January 30, 2018 (Ermächtigungsbeschluss), or any other maximum amount authorized by any shareholders meeting subsequent
to the effective date of this Agreement; and


 


(ii)       all
statutory pre-emptive rights to which the existing shareholders of the Company are entitled under Swiss law with respect to the
capital increase described in Section 2(d)(i) have been or will be validly set aside or waived.


 


(e)       Capital
Increase Account. The Company confirms that it has opened with (i) UBS AG, bank clearing no. referenced in Schedule 2(e)
hereto (the “Capital Increase Bank”), a blocked account for the capital increase (Kapitaleinzahlungskonto)
set forth in Schedule 2(e) hereto made out to “AURIS MEDICAL HOLDING AG KAPITALERHÖHUNG” (the “Capital
Increase Account”), and (ii) UBS AG, ABA no. referenced in Schedule 2(e) hereto (the “General Account
Bank”), an account for the capital surplus, account no. set forth in Schedule 2(e) hereto made out to “AURIS
MEDICAL HOLDING AG” (the “General Account”). The Company may replace the then current Capital Increase
Account with another account with the Capital Increase Bank by giving written notice of such change to the Investor, at which
point such new account shall become the Capital Increase Account. A Capital Increase Account shall remain open until the earlier
of (i) the Maturity Date and (ii) the date on which this Agreement is properly terminated pursuant to and in accordance with Section
11 and the full amount of any then remaining Capital Increase Amount therein that is not subject to any then pending Regular Purchase


 




    -9-


     


    

Notice or
Additional Purchase Notice is returned to the Investor and the Investor has confirmed receipt thereof in full.


 


(f)       Subscription
of Capital Increase. On the applicable Purchase Date for a Regular Purchase and/or Additional Purchase, as applicable, the
Investor shall subscribe for all of the Purchase Shares relating to such Regular Purchase and/or Additional Purchase, as applicable,
at the issue price (Ausgabebetrag) per Purchase Share equal to the Issue Price, and shall deliver or cause to be delivered
to the Company an original copy of the corresponding subscription form (Zeichnungsschein) in the form of Exhibit
A to the Company, duly executed by the Investor.


 


(g)       Board
Resolution and Registration of Capital Increase. Provided the Company has received the applicable written confirmation of
payment of the applicable Capital Increase Amount in accordance with Section (2)(c)(i), the applicable subscription form
in accordance with Section 2(f), and the applicable confirmation of the deposit of the applicable Purchase Amount Balance
in accordance with Section 2(c)(ii), then, no later than 9:00 a.m. (CEST) on the applicable Closing Date, the Board (or
a committee or a Board member duly authorized by the Board) shall: (i) pass a capital increase resolution (Erhöhungsbeschluss)
regarding the issuance of all of the Purchase Shares relating to such purchase(s) subscribed for pursuant to Section 2(f)
(each such resolution, a “Capital Increase”), (ii) adopt a report on such Capital Increase (Kapitalerhöhungsbericht)
and, after having caused the special auditor to issue the auditors' report (Prüfungsbestätigung), take note of
the auditors’ report (Prüfungsbestätigung), all in accordance with Swiss statutory law, (iii) resolve on
such Capital Increase and making all amendments to the articles of association of the Company necessary in connection with such
Capital Increase (Feststellungs- und Statutenänderungsbeschluss), and (iv) promptly thereafter, and not later than
11:00 a.m. (CEST) on the applicable Closing Date, file the documents necessary for the registration of such Capital Increase with
the Commercial Register of the Canton of Zug. Any fees payable to the Capital Increase Bank for any transfer of the funds deposited
in the Capital Increase Account pursuant to this Section 2(g) shall be payable immediately and directly to the Capital
Increase Bank by the Company.


 


(h)       Issue
of Purchase Shares. Provided the Company has received the applicable written confirmation of payment of the applicable Capital
Increase Amount in accordance with Section (2)(c)(i), the applicable subscription form in accordance with Section 2(f),
and the applicable confirmation of the deposit of the applicable Purchase Amount Balance in accordance with Section 2(c)(ii),
then, immediately after the registration of the Capital Increase in the Commercial Register of the Canton of Zug pursuant to Section
2(g), but in no event later than 2:30 p.m. (CEST) on the applicable Closing Date, the Company will:


 


(i)       deliver
to the Investor and the Capital Increase Bank, (A) a copy of the certified excerpt of the journal entry (Tagebuch) or a
copy of the certified excerpt from the Commercial Register of the Canton of Zug evidencing such Capital Increase, (B) a copy of
the certified updated articles of association of the Company evidencing such Capital Increase, and (C) a copy of the Company's
book of uncertificated securities (Wertrechtebuch) evidencing the Investor as first holder of such applicable Purchase
Shares; and


 


(ii)       take
all steps necessary to ensure that all such applicable Purchase Shares will be timely delivered to the Investor as DWAC Shares
on the applicable Closing Date in accordance with this Section 2.


 


(i)       Use
of Capital Increase Amount. The funds deposited in the Capital Increase Account shall, upon registration of the Capital Increase
pursuant to Section 2(g) and upon written request by the Company, be transferred to a separate account of the Company with
UBS AG and shall, in such case,


 




    -10-


     


    

remain
so deposited for the account of the Company and shall not be used in any way whatsoever until the delivery to the Investor of
all of the Purchase Shares to be issued to the Investor in connection with such applicable purchase(s) as DWAC Shares pursuant
to and in accordance with Section 2(c)(ii). Any fees payable to the Capital Increase Bank for any transfer of the funds
deposited in the Capital Increase Account pursuant to this Section 2(i) shall be payable directly to the Capital Increase
Bank by the Company.


 


(j)       Beneficial
Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not offer, issue
or sell, and the Investor shall not subscribe for, purchase or acquire, any Common Shares under this Agreement which,
when aggregated with all other Common Shares then beneficially owned by the Investor (as calculated pursuant to Section 13(d)
of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor of more
than 4.99% of the then issued and outstanding Common Shares (the “Beneficial Ownership Limitation”). Upon
the written or oral request of the Investor, the Company shall promptly (but not later than 24 hours) confirm orally or in writing
to the Investor the number of Common Shares then outstanding. The Investor and the Company shall each cooperate in good faith
in the determinations required hereby and the application hereof. The Investor’s written certification to the Company of
the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive
with respect to the applicability thereof and such result absent manifest error.


 


3.       INVESTOR'S
REPRESENTATIONS AND WARRANTIES.


 


The
Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date:


 


(a)       Organization.
The Investor is an entity duly organized, validly existing and in good standing under the laws of its jurisdiction of organization,
with the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder.


 


(b)       Investment
Purpose.  The Investor is acquiring the Purchase Shares as principal for its own account for investment only and not
with a view to or for distributing or reselling such Purchase Shares or any part thereof in violation of the Securities Act or
any applicable state securities law, has no present intention of distributing any of such Purchase Shares in violation of the
Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other
Persons to distribute or regarding the distribution of such Purchase Shares in violation of the Securities Act or any applicable
state securities law (this representation and warranty not limiting the Investor’s right to sell the Purchase Shares at
any time pursuant to the Registration Statement described herein or otherwise in compliance with the Securities Act and applicable
state securities laws).  The Investor is acquiring the Purchase Shares hereunder in the ordinary course of its business.


 


(c)       Accredited
Investor Status. The Investor is an "accredited investor" as that term is defined in Rule 501(a)(3) of Regulation
D promulgated under the Securities Act.


 


(d)       Reliance
on Exemptions. The Investor understands that the Purchase Shares are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and the Investor's compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility
of the Investor to acquire the Purchase Shares.


 




    -11-


     


    

(e)       Information.
The Investor understands that its investment in the Purchase Shares involves a high degree of risk. The Investor (i) is able to
bear the economic risk of an investment in the Purchase Shares including a total loss thereof, (ii) has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Purchase
Shares and (iii) has had an opportunity to ask questions of and receive answers from the officers of the Company concerning the
financial condition and business of the Company and others matters related to an investment in the Purchase Shares. Neither such
inquiries nor any other due diligence investigations conducted by the Investor or its representatives shall modify, amend or affect
the Investor's right to rely on the Company's representations and warranties contained in Section 4 below. The Investor
has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect
to its acquisition of the Purchase Shares.


 


(f)       No
Governmental Review. The Investor understands that no U.S. federal or state agency or any other domestic or foreign government
or governmental agency has passed on or made any recommendation or endorsement of the Purchase Shares or the fairness or suitability
of an investment in the Purchase Shares nor have such authorities passed upon or endorsed the merits of the offering of the Purchase
Shares.


 


(g)       Transfer
or Sale. The Investor understands that (i) the Purchase Shares may not be offered for sale, sold, assigned or transferred
unless (A) registered pursuant to the Securities Act or (B) an exemption exists permitting such Purchase Shares to be sold, assigned
or transferred without such registration; (ii) any sale of the Purchase Shares made in reliance on Rule 144 may be made only in
accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Purchase Shares under circumstances
in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined
in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations
of the SEC thereunder.


 


(h)       Validity;
Enforcement. Each of this Agreement and the Registration Rights Agreement has been duly and validly authorized, executed and
delivered on behalf of the Investor and is a valid and binding agreement of the Investor enforceable against the Investor in accordance
with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights
and remedies.


 


(i)       Residency.
The Investor is a resident of the State of Illinois.


 


(j)       No
Short Selling. The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has
the Investor, or any of its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or
indirectly, any (i) "short sale" (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the
Common Shares or (ii) hedging transaction, which establishes a net short position with respect to the Common Shares.


 


4.       REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.


 


The
Company represents and warrants to the Investor that, except as set forth in the disclosure schedules attached hereto, which exceptions
shall be deemed to be a part of the representations and warranties made hereunder, as of the date hereof and as of the Commencement
Date:


 


(a)       Organization
and Qualification. The Company has been duly incorporated and is validly existing under the laws of Switzerland and has the
corporate power and authority to own, lease and


 




    -12-


     


    

operate
its properties and to conduct its business as described in the SEC Documents and to enter into and perform its obligations under
this Agreement. The Company is duly qualified as a foreign corporation to transact business in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct of business. Each of the Company’s
Subsidiaries has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership
or limited liability company, as applicable, in good standing (where such concept exists) under the laws of the jurisdiction of
its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties
and to conduct its business as described in the SEC Documents. Each of the Company’s Subsidiaries is duly qualified as a
foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in
each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct
of business, except where the failure to be so qualified or in good standing (where such concept exists) would not, individually
or in the aggregate, result in a Material Adverse Effect. Except as described in the SEC Documents, all of the issued and outstanding
capital stock or other equity or ownership interests of each of the Company’s Subsidiaries have been duly authorized and
validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear
of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly
or indirectly, any corporation, association or other entity other than the Subsidiaries disclosed in the Company’s annual
report on Form 20-F for the year ended December 31, 2017. Except as described in the SEC Documents, no Subsidiary of the Company
is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution
with respect to such Subsidiary’s equity securities or from repaying to the Company or any other Subsidiary of the Company
any amounts that may from time to time become due under any loans or advances to such Subsidiary from the Company or from transferring
any property or assets to the Company or to any other Subsidiary.


 


(b)       Authorization;
Enforcement; Validity. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement and each of the other Transaction Documents to which it is a party, and to issue the Purchase Shares in accordance
with the terms hereof and thereof, (ii) the execution and delivery by the Company of the Transaction Documents to which it is
a party and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the reservation
for issuance and the issuance of the Purchase Shares issuable under this Agreement, have been duly authorized by the Board and
no further consent or authorization is required by the Company, the Board or the Company’s shareholders, (iii) this Agreement
has been, and each other Transaction Document to which the Company is a party shall be on the Commencement Date, duly executed
and delivered by the Company and (iv) this Agreement constitutes, and each other Transaction Document to which the Company is
a party upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company enforceable
against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity
or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally,
the enforcement of creditors' rights and remedies, and except that such enforceability may be further limited by the Company’s
current articles of association which limit the power of the Board to issue shares based on authorized share capital to 3,050,000
shares until January 29, 2020. Except as set forth in this Agreement, no other approvals or consents of the Board, any authorized
committee thereof, or shareholders of the Company is necessary under applicable Swiss or other laws, rules or regulations, or
under the Company’s articles of association or similar organizational documents, to authorize the execution and delivery
of this Agreement or any of the other Transaction Documents to which the Company is a party, or any of the transactions contemplated
hereby or thereby, including, but not limited to, the offer, issuance and sale of the Purchase Shares to the Investor.


 




    -13-


     


    

(c)       Capitalization.
The authorized, issued and outstanding share capital of the Company is as set forth in the Company’s annual report on Form
20-F for the year ended December 31, 2017 (other than for subsequent issuances, if any, pursuant to employee benefit plans, or
upon the exercise of outstanding options or conversion rights, in each case described in the Company’s annual report on
Form 20-F for the year ended December 31, 2017). The share capital of the Company, including the Purchase Shares, conforms in
all material respects to the description thereof contained in the Prospectus. All of the issued and outstanding Common Shares
have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all applicable
securities laws. Except as described in the SEC Documents, none of the outstanding Common Shares was issued in violation of any
preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. The
Common Shares conform to the law of the jurisdiction of the Company’s incorporation and to any requirements of the Company’s
organizational documents. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal
or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock
of the Company or any of its Subsidiaries other than those described in the SEC Documents. The descriptions of the Company’s
stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth
in the SEC Documents accurately and fairly presents the information required to be shown with respect to such plans, arrangements,
options and rights. Except as described in the SEC Documents, there are no persons with registration or other similar rights to
have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated
by this Agreement, except for such rights as have been duly withdrawn or waived.


 


(d)       Issuance
of Purchase Shares. The Purchase Shares, when issued and delivered by the Company against payment therefor pursuant to this
Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Purchase Shares is not subject
to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Purchase Shares which
have not been duly withdrawn waived or satisfied. Upon the sale and delivery to the Investor of the Purchase Shares, and payment
therefor, the Investor will acquire good, marketable and valid title to such Purchase Shares, free and clear of all pledges, liens,
security interests, charges, claims or encumbrances.


 


(e)       No
Conflicts. Neither the Company nor any of its Subsidiaries is in violation of its articles of association or operating agreement
or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be
in default) (“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract,
franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument
or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its Subsidiaries is
a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each,
an “Existing Instrument”), except for such Defaults as would not be expected, individually or in the aggregate,
to have a Material Adverse Effect. The Company’s execution, delivery and performance of this Agreement and the other Transaction
Documents to which it is a party, consummation of the transactions contemplated hereby and thereby and the issuance and sale of
the Purchase Shares pursuant to this Agreement (i) have been duly authorized by all necessary corporate action and will not
result in any violation of the provisions of the articles of association or operating agreement or similar organizational documents,
as applicable, of the Company or any Subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt
Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company or any of its Subsidiaries pursuant to, or require the consent of any other party to,
any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative
or court decree applicable to the Company or any of its Subsidiaries except, as to clauses (ii) and (iii), as would not be expected,
individually or in the aggregate, to have a Material Adverse Effect. No consent, approval, authorization or other order of, or
registration or


 




    -14-


     


    

filing
with, any court or other governmental or regulatory authority or agency, is required for the Company’s execution, delivery
and performance of this Agreement or any of the other Transaction Documents to which it is a party and consummation of the transactions
contemplated hereby and thereby, except such as have been obtained or made by the Company and are in full force and effect and
such as may be required under the Securities Act, applicable U.S. state securities or “blue sky” laws, or the Principal
Market. Except as set forth elsewhere in this Agreement, all consents, authorizations, orders, filings and registrations which
the Company is required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement
Date. As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with
the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any
person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or any of its Subsidiaries. The Company and its Subsidiaries have been and are in compliance
with all applicable laws, rules and regulations, except where failure to be so in compliance would not be expected, individually
or in the aggregate, to have a Material Adverse Effect.


 


(f)       SEC
Documents; Financial Statements. The Company has filed with the SEC all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the twelve months preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein,
being collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension.  As of their
respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable. None of the SEC Documents, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements filed with the SEC as a part of or incorporated by reference
in the SEC Documents present fairly, in all material respects, the consolidated financial position of the Company and its Subsidiaries
as of the dates indicated and the results of their operations, changes in stockholders’ equity and cash flows for the periods
specified. Such financial statements have been prepared in conformity with International Financial Reporting Standards (“IFRS”)
as issued by the International Accounting Standards Board (the “IASB”) applied on a consistent basis throughout
the periods involved, except as may be expressly stated in the related notes thereto or as otherwise disclosed therein, and, in
the case of interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes.
No other financial statements or supporting schedules are required to be included in the SEC Documents. To the Company’s
knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has
failed to comply with any sanction pursuant to Rule 5300 promulgated by the Public Company Accounting Oversight Board (“PCAOB”),
has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other
financial data filed with the SEC as a part of or incorporated by reference in the SEC Documents. Except as set forth in the SEC
Documents, the Company has received no notices or correspondence from the SEC for the one year preceding the date hereof. The
SEC has not commenced any enforcement proceedings against the Company or any of its Subsidiaries.


 


(g)       Absence
of Certain Changes. Except as otherwise disclosed in the SEC Documents, subsequent to the respective dates as of which information
is given in the SEC Documents: (i) there has been no material adverse change, or any development that could be expected to
result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations,
assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company
and its Subsidiaries, considered as one entity (any such change being


 




    -15-


     


    

referred
to herein as a “Material Adverse Change”); (ii) the Company and its Subsidiaries, considered as one entity,
have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses
or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered
by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually
or in the aggregate, to the Company and its Subsidiaries, considered as one entity, or have entered into any transactions not
in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material
increase in any short-term or long-term indebtedness of the Company or its Subsidiaries and there has been no dividend or distribution
of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other Subsidiaries, by any of
the Company’s Subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its Subsidiaries
of any class of capital stock. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection
pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its
creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally
able to pay its debts as they become due. Except for Auris Medical AG, whose overindebtedness is covered by subordination of claims
of the Company, neither the Company nor its Swiss Subsidiaries are overindebted or suffering from capital loss within the meaning
of article 725 of the Swiss Code of Obligations (the “CO”).


 


(h)       Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity
now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its Subsidiaries, which
would be expected, individually or in the aggregate, to have a Material Adverse Effect; and the aggregate of all pending legal
or governmental proceedings to which the Company or any such Subsidiary is a party or of which any of their respective properties
or assets is the subject, including ordinary routine litigation incidental to the business, if determined adversely to the Company,
would not be expected to have a Material Adverse Effect. No material labor dispute with the employees of the Company or any of
its Subsidiaries exists or, to the knowledge of the Company, is threatened or imminent.


 


(i)       Acknowledgment
Regarding Investor's Status. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm's
length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further
acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor
or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby
and thereby is merely incidental to the Investor's subscription for the Purchase Shares. The Company further represents to the
Investor that the Company's decision to enter into the Transaction Documents has been based solely on the independent evaluation
by the Company and its representatives and advisors.


 


(j)       No
General Solicitation; No Integrated Offering. None of the Company, any of its affiliates, or any Person acting on its or their
behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities
Act) in connection with the offer or sale of the Purchase Shares. None of the Company, any of its affiliates, or any Person acting
on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any
security, under circumstances that would cause this offering of the Purchase Shares to be “integrated” (within the
meaning of the Securities Act) with any prior offering of securities by the Company. The offer, issuance and sale of the Purchase
Shares hereunder does not contravene the rules and regulations of the Principal Market.


 




    -16-


     


    

(k)       Intellectual
Property Rights. Except as described in the SEC Documents, the Company, to the best of its knowledge, owns or has valid, binding
and enforceable licenses or other enforceable rights under the patents and patent applications, copyrights, trademarks, trademark
registrations, service marks, service mark registrations, trade names, service names and know-how (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) as described in the SEC Documents
and used in the conduct, or the proposed conduct, of the business of the Company in the manner described in the SEC Documents
(collectively, the “Company Intellectual Property”); except as described in the SEC Documents, to the knowledge
of the Company, the patents, trademarks, and copyrights included within the Company Intellectual Property are valid, enforceable,
and subsisting, and there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by
others challenging the validity, enforceability or scope of any Company Intellectual Property; other than as disclosed in the
SEC Documents, (i) the Company has not received any notice of any claim of infringement, misappropriation or conflict with any
asserted rights of others with respect to any of the Company’s products, proposed products or processes, (ii) to the knowledge
of the Company, neither the sale nor use of any of products, proposed products or processes of the Company referred to in the
SEC Documents do or will, to the knowledge of the Company, infringe, any valid patent claim of any third party or violate any
valid right of any third party, and (iii) to the knowledge of the Company, no third party has any ownership right in or to any
Company Intellectual Property that is owned by the Company, other than any co-owner of any patent or pending patent application
constituting Company Intellectual Property who is listed on the records of the U.S. Patent and Trademark Office (the “USPTO”)
, and, to the knowledge of the Company, no third party has any ownership right in or to any Company Intellectual Property in any
field of use that is exclusively licensed to the Company, other than any licensor to the Company of such Company Intellectual
Property; except as described in the SEC Documents, none of the technology employed by the Company has been obtained or is being
used by the Company in violation of any contractual obligation binding on the Company except as would not be expected, individually
or in the aggregate, to have a Material Adverse Effect, or, to the Company’s knowledge, upon any of its officers, directors
or employees; except as described in the SEC Documents, to the knowledge of the Company all patents and patent applications owned
by and licensed to the Company or under which the Company has rights have been duly and properly filed and maintained; to the
knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to
the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO
that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or
could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.


 


(l)       Environmental
Laws. Except as described in the SEC Documents and except as would not be expected, individually or in the aggregate, to have
a Material Adverse Effect: (i) neither the Company nor any of its Subsidiaries is in violation of any federal, state, local or
foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation
thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human
health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata)
or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous
Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling
of Hazardous Materials (collectively, “Environmental Laws”); (ii) the Company and its Subsidiaries have all
permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements;
(iii) there are no pending or, to the Company’s knowledge, threatened administrative, regulatory or judicial actions, suits,
demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental
Law against the Company or any of its Subsidiaries; and (iv) to the Company’s knowledge


 




    -17-


     


    

there
are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or
an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of
its Subsidiaries relating to Hazardous Materials or any Environmental Laws.


 


(m)       Title.
The Company and its Subsidiaries have good and marketable title to all of the real and personal property and other assets reflected
as owned in the financial statements referred to in Section 4(f) above (or elsewhere in the SEC Documents), in each case
free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as
otherwise disclosed in the SEC Documents or as would not reasonably be expected to have a Material Adverse Effect. The real property,
improvements, equipment and personal property held under lease by the Company or any of its Subsidiaries are held under valid
and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed
to be made of such real property, improvements, equipment or personal property by the Company or such Subsidiary.


 


(n)       Insurance.
Except as described in the SEC Documents, each of the Company and its Subsidiaries are insured with policies in such amounts and
with such deductibles and covering such risks as the Company believes are adequate and customary for their businesses including,
but not limited to, policies covering real and personal property owned or leased by the Company and its Subsidiaries against theft,
damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its Subsidiaries for product liability
claims and clinical trial liability claims. The Company has no reason to believe that it or any of its Subsidiaries will not be
able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would
not be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has been denied any insurance
coverage which it has sought or for which it has applied.


 


(o)       Regulatory
Permits. The Company and its Subsidiaries possess such valid and current certificates, authorizations, exemptions, approvals,
clearances or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses
as currently conducted and as described in the SEC Documents (“Permits”). Neither the Company nor any of its
Subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to
the revocation or modification of, or non-compliance with, any such certificate, authorization or permit except where such revocation
or modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.


 


(p)       Tax
Status. Except where the failure to do so would not constitute a Material Adverse Effect, (a) all tax returns (including tax
refund requests) required to be filed pursuant to applicable law by or with respect to the Company and any of its Subsidiaries
have been timely filed, or proper request of extension thereof has been filed, and (b) all tax returns filed are complete and
correct, and all taxes, fines or penalties due including any interest and penalties, except tax deficiencies that the Company
or any of its Subsidiaries are contesting in good faith subject to applicable reserves, have been timely paid and fully reserved
against in the applicable financial statements referred to in Section 4(f) above. Except as disclosed in the SEC Documents,
no stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding, value added, capital or other
taxes (but excluding any income tax, capital gains tax or similar resulting from the sale of the Purchase Shares by the Investor)
are payable by or on behalf of the Investor to any Swiss tax authorities or any political subdivisions or taxing authority thereof
or therein in connection with (i) the issuance of the Purchase Shares, (ii) the execution and delivery of this Agreement or any
other Transaction Document, and (iii) the offer, sale, delivery and resale of the Purchase Shares in the manner contemplated in
the Registration Statement, the Prospectus and this Agreement.


 




    -18-


     


    

(q)       Transactions
With Related Parties.  There are no business relationships or related-party transactions involving the Company or any
of its Subsidiaries or any other Person required to be described in the SEC Documents that have not been described as required.
There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or
guarantees of indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their
respective family members, except as disclosed in the SEC Documents. All transactions by the Company with office holders or control
persons of the Company have been duly approved by the Board, or duly appointed committees or officers thereof, if and to the extent
required under U.S. federal law.


 


(r)       No
Contract Terminations. Neither the Company nor any of its Subsidiaries has sent or received any communication regarding termination
of, or intent not to renew, any of the contracts or agreements referred to or described in the SEC Documents, or referred to or
described in, or filed as an exhibit to, any SEC Document, or any document incorporated by reference therein, and no such termination
or non-renewal has been threatened by the Company or any of its Subsidiaries or, to the Company’s knowledge, any other party
to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof, except
where such termination or non-renewal would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.


 


(s)        Disclosure.  Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents that will be timely
publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided
the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public
information which is not otherwise disclosed in the SEC Documents.   The Company understands and confirms that
the Investor will rely on the foregoing representation in effecting purchases and sales of securities of the Company.   None
of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business and the transactions
contemplated hereby, including the disclosure schedules to this Agreement contains any untrue statement of a material fact or
omits to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which
they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of
this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made and when made, not misleading.  The Company acknowledges and agrees that the Investor neither makes nor has made
any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth
in Section 3 hereof.


 


(t)       Foreign
Corrupt Practices.  Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director,
officer, agent, employee, affiliate or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course
of its actions for, or on behalf of, the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment
to any domestic government official, “foreign official” (as defined in the U.S. Foreign Corrupt Practices Act of 1977,
as amended, and the rules and regulations thereunder (collectively, the “FCPA”) or employee from corporate
funds; (iii) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or
regulation; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any
domestic government official, such foreign official or employee; and the Company and its Subsidiaries and, to the knowledge of
the Company, the Company’s affiliates have conducted their respective businesses in compliance with the


 




    -19-


     


    

FCPA
and have instituted policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith.


 


(u)       No
Unlawful Contributions or Other Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s knowledge,
any employee or agent of the Company or any Subsidiary, has made any contribution or other payment to any official of, or candidate
for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the SEC Documents.


 


(v)
       Money Laundering Laws. The operations of the Company and its Subsidiaries are,
and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions,
the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries
with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.


 


(w)       OFAC.
Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee,
affiliate or Person acting on behalf of the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not
directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any
Subsidiary, or any joint venture partner or other Person, for the purpose of financing the activities of or business with any
Person, or impermissibly in any country or territory, that currently is the subject to any U.S. sanctions administered by OFAC
or in any other manner that will result in a violation by any Person (including any Person participating in the transactions contemplated
by the Transaction Documents, whether as investor or otherwise) of U.S. sanctions administered by OFAC.


 


(x)       DTC
Eligibility. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer
(FAST) Program and the Common Shares, including the Purchase Shares, can be transferred electronically to third parties via the
DTC Fast Automated Securities Transfer (FAST) Program.


 


(y)
       Company’s Accounting System. The Company and each of its Subsidiaries make
and keep accurate books and records and maintain a system of internal accounting controls designed to provide reasonable assurance
that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with IFRS as issued by IASB and to maintain
accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific
authorization and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.


 


(z)       Disclosure
Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The Company has established
and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which are
designed to ensure that material information relating to the Company, including its consolidated Subsidiaries, is made known to
the Company’s principal executive officer and its principal financial officer by others within those entities and are effective
in all material respects to perform the functions for which they were established. Since the end of the Company’s most recent
audited fiscal year, there has been no material weakness in the


 




    -20-


     


    

Company’s
internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over
financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control
over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred
that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company’s internal
control over financial reporting.


 


(aa)Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made
by or on behalf of other Persons for fees of a type contemplated in this Section 4(aa) that may be due in connection with
the transactions contemplated by the Transaction Documents.


 


(bb)Investment
Company. The Company is not, and will not be, either after receipt of payment for the Purchase Shares or after the application
of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement or the Prospectus, required
to register as an “investment company” under the Investment Company Act of 1940, as amended (the “Investment
Company Act”).


 


(cc)Listing
and Maintenance Requirements. The Common Shares are registered pursuant to Section 12(b) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Shares pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating
terminating such registration. Except as described in the SEC Documents, the Company has not, in the twelve (12) months preceding
the date hereof, received any notice from any Person to the effect that the Company is not in compliance with the listing or maintenance
requirements of the Principal Market. Except as described in the SEC Documents, the Company is, and has no reason to believe that
it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Principal
Market has not commenced any delisting proceedings against the Company. The Purchase Shares have been approved for listing on
the Principal Market.


 


(dd)Accountants.
Deloitte AG, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes
the related notes thereto) filed with the SEC as a part of the Company’s annual report on Form 20-F for the year ended December
31, 2017, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act and the
rules of the PCAOB, (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule
2-01 of Regulation S-X under the Securities Act, (iii) a registered public accounting firm as defined by the PCAOB whose registration
has not been suspended or revoked and who has not requested such registration to be withdrawn and (iv) an independent qualified
public accountant qualified under the applicable provisions of the CO, the Swiss Audit Supervision Act (Revisionsaufsichtsgesetz)
and any ordinances promulgated thereunder.


 


(ee)No
Market Manipulation. The Company has not, and to its knowledge no Person acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Purchase Shares, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Purchase Shares, or (iii) paid or agreed to pay to any Person any compensation for
soliciting another to purchase any other securities of the Company.


 


(ff)Statistical
and Market-Related Data. All statistical, demographic and market-related data included in the SEC Documents are based on or
derived from sources that the Company believes, to be


 




    -21-


     


    

reliable
and accurate in all material respects. To the extent required, the Company has obtained the written consent to the use of such
data from such sources.


 


(gg)Forward-Looking
Statements. Each financial or operational projection or other “forward-looking statement” (as defined by Section
27A of the Securities Act or Section 21E of the Exchange Act) contained in the SEC Documents (i) was so included by the Company
in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other
applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors
that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made
with the knowledge of an executive officer or director of the Company that is was false or misleading.


 


(hh)Foreign
Private Issuer; Emerging Growth Company. The Company is a “foreign private issuer” within the meaning of Rule
405 under the Securities Act. The Company has been and is an “emerging growth company,” as defined in Section 2(a)(19)
of the Securities Act.


 


(ii)       Clinical
Data and Regulatory Compliance. The preclinical tests and clinical trials conducted by the Company, and to the knowledge of
the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described
in, or the results of which are referred to in, the SEC Documents were and, if still pending, are being conducted in all material
respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical
and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50,
54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly
presents the data derived from such studies, and the Company and its Subsidiaries have no knowledge of any other studies the results
of which are inconsistent with, or otherwise call into question, the results described or referred to in the SEC Documents; the
Company and its Subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug
Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign
government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the
“Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor
any of its Subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension
or modification of any clinical trials that are described or referred to in the SEC Documents; and the Company and its Subsidiaries
have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory
Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.


 


(jj)
    Compliance with Health Care Laws. Except as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect, each of the Company and its Subsidiaries is, and at all times has been, in compliance
with all applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability,
civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state health care program or federal
health care program. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug,
and Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, local and all applicable foreign
health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)),
the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the U.S. Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h),
the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)),
all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286


 




    -22-


     


    

and
287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996
(“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), the civil monetary
penalties law (42 U.S.C. § 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such statutes; (iii) Medicare (Title XVIII
of the Social Security Act); (iv) Medicaid (Title XIX of the Social Security Act); and (v) any and all other applicable health
care laws and regulations. Neither the Company nor, to the knowledge of the Company, its Subsidiary has received written notice
of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation
of any Health Care Laws, and, to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action is threatened. Neither the Company nor, to the knowledge of the Company, its Subsidiary
is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements,
monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental
or regulatory authority. Additionally, neither the Company, its Subsidiaries nor any of its respective employees, officers or
directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical
research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar
action that could reasonably be expected to result in debarment, suspension, or exclusion.


 


(kk)Suppliers.
Customers, Distributors and Sales Agents. No supplier, customer, distributor or sales agent of the Company has notified
the Company that it intends to discontinue or decrease the rate of business done with the Company, except
where such decrease is not reasonably likely to result in a Material Adverse Effect.


 


(ll)
ERISA Compliance. The “employee benefit plans” (as defined under the Employee Retirement Income Security
Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”))
sponsored or maintained by the Company or its Subsidiaries are operated in compliance in all material respects with ERISA to the
extent applicable, except where the failure to be in compliance would not be expected to have a Material Adverse Effect. 
“ERISA Affiliate” means, with respect to the Company or any of its Subsidiaries, any entity that is treated
as a single employer with the Company or any of its Subsidiaries under Sections 414(b), (c), (m) or (o) of the Internal Revenue
Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”). 
Neither the Company, its Subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability
under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (ii)
Sections 412, 4971, 4975 or 4980B of the Code that would reasonably be expected to be a material liability of the Company. 
Neither the Company nor any of its Subsidiaries (i) sponsors or maintains any plan that is subject to Title
IV of ERISA or is intended to be qualified under Section 401(a) of the Code or (ii) reasonably expects to incur any
material liability under Title IV of ERISA.


 


(mm)PFIC
Status. As of December 31, 2017, the Company believes that it was a “passive foreign investment company,”
as such term is defined in the Code. Neither the Company nor any Subsidiary of the Company is, and, after giving effect to
the offering, issuance and sale of the Purchase Shares to the Investor and the application of the proceeds thereof, none of them
will be, a “controlled foreign corporation” as defined by the Code.


 


(nn)Submission
to Jurisdiction. The Company has the power to submit, and pursuant to Section 12(a) of this Agreement, has legally, validly,
effectively and irrevocably submitted, to the personal jurisdiction of each United States federal court and New York state court
located in the State of


 




    -23-


     


    

New
York, Borough of Manhattan, in the City of New York, New York, U.S.A. (each, a “New York Court”), and the Company
has the power to designate, appoint and authorize, and pursuant to Section 12(a) of this Agreement, has legally, validly,
effectively and irrevocably designated, appointed and authorized the an agent for service of process in any action arising out
of or relating to the Purchase Shares, this Agreement or any of the other Transaction Documents or any of the transactions contemplated
hereby or thereby in any New York Court, and service of process effected on such authorized agent will be effective to confer
valid personal jurisdiction over the Company as provided in Section 12(a) hereof.


 


(oo)       No
Rights of Immunity. Except as provided by laws or statutes generally applicable to transactions of the type described in this
Agreement, neither the Company nor any of its respective properties, assets or revenues has any right of immunity under Swiss,
Illinois or United States law, from any legal action, suit or proceeding, from the giving of any relief in any such legal action,
suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Swiss, Illinois or United States federal court,
from service of process, attachment upon or prior judgment, or attachment in aid of execution of judgment, or from execution of
a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such
court, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with this Agreement
or any of the other Transaction Documents. To the extent that the Company or any of its respective properties, assets or revenues
may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings may at any time
be commenced, the Company waives or will waive such right to the extent permitted by law and has consented to such relief and
enforcement as provided in Section 12(a) of this Agreement.


 


(pp)Shell
Company Status. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the Securities
Act.


 


(qq)No
Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company's
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered
Person”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule
506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered
Person is subject to a Disqualification Event.


 


5.       COVENANTS.


 


(a)       Filing
of Current Report and Registration Statement. The Company agrees that it shall, not later than 9:00 a.m., Eastern Time on
the Business Day immediately following the date of this Agreement, file with the SEC a report on Form 6-K relating to the transactions
contemplated by, and describing the material terms and conditions of, the Transaction Documents, and attaching a copy of this
Agreement as an Exhibit thereto (the “Current Report”). The Company shall also file with the SEC, within ten
(10) days from the date hereof, a new registration statement (the “Registration Statement”) covering only the
resale of the Purchase Shares, in accordance with the terms of the Registration Rights Agreement between the Company and the Investor,
dated as of the date hereof (the “Registration Rights Agreement”). The Company shall permit the Investor to
review and comment upon a substantially complete pre-filing draft of the Current Report and the Registration Statement at least
two (2) Business Days prior to their filing with the SEC, and the Company shall give reasonable consideration to all such comments.
The Investor shall use its reasonable best efforts to comment upon the Current Report and the


 




    -24-


     


    

Registration
Statement within one (1) Business Day from the date the Investor receives such substantially complete pre-filing draft versions
thereof from the Company. The Investor shall furnish to the Company such information regarding itself, the Common Shares, including
any Purchase Shares, beneficially owned by it and the intended method of distribution of the Purchase Shares, including any arrangement
between the Investor and any other Person relating to the sale or distribution of the Purchase Shares, as shall be reasonably
requested by the Company in connection with the preparation and filing of the Current Report and the Registration Statement, and
shall otherwise cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing
of the Current Report and the Registration Statement with the SEC.


 


(b)       Blue
Sky. The Company shall use its reasonable best efforts to take all such action, if any, as is reasonably necessary in order
to obtain an exemption for or to register or qualify (i) the sale of the Purchase Shares to the Investor under this Agreement
and (ii) any subsequent resale of all Purchase Shares by the Investor, in each case, under applicable securities or “Blue
Sky” laws of the states of the United States in such states as is reasonably requested by the Investor from time to time,
and shall provide evidence of any such action so taken to the Investor.


 


(c)       Listing/DTC.
The Company shall promptly secure the listing of all of the Purchase Shares to be issued to the Investor under this Agreement
on the Principal Market (subject to official notice of issuance) and upon each other national securities exchange or automated
quotation system, if any, upon which the Common Shares are then listed, and shall use commercially reasonable efforts to maintain,
so long as any shares of Common Shares shall be so listed, such listing of all such Purchase Shares. The Company shall use commercially
reasonable efforts to maintain the listing of the Common Shares, including the Purchase Shares, on the Principal Market and shall
comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules and regulations
of the Principal Market. Neither the Company nor any of its Subsidiaries shall take any action that would reasonably be expected
to result in the delisting or suspension of the Common Shares, including the Purchase Shares, on the Principal Market. The Company
shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any notices it receives
from the Principal Market regarding the continued eligibility of the Common Shares for listing on the Principal Market; provided,
however, that the Company shall not be required to provide the Investor copies of any such notice that the Company reasonably
believes constitutes material non-public information and the Company would not be required to publicly disclose such notice in
any report or statement filed with the SEC under the Exchange Act (including on Form 6-K) or the Securities Act. The Company shall
pay all fees and expenses in connection with satisfying its obligations under this Section 5(c). The Company shall take
all action necessary to ensure that its Common Shares, including the Purchase Shares, can be transferred electronically as DWAC
Shares.


 


(d)       Prohibition
of Short Sales and Hedging Transactions. The Investor agrees that beginning on the date of this Agreement and ending on the
date of termination of this Agreement as provided in Section 11, the Investor and its agents, representatives and affiliates shall
not in any manner whatsoever enter into or effect, directly or indirectly, any (i) “short sale” (as such term is defined
in Rule 200 of Regulation SHO of the Exchange Act) of the Common Shares or (ii) hedging transaction, which establishes a net short
position with respect to the Common Shares.


 


(e)       Payment
of Commitment Fee. In consideration for the Investor’s execution and delivery of this Agreement, the Company shall cause
to be paid to the Investor a commitment fee of US$250,000 (the “Commitment Fee”) immediately upon the execution
of this Agreement and shall deliver the Commitment Fee in full to the Investor by wire transfer of immediately available funds
to an account designated by the Investor by written notice to the Company on or prior to the date of this Agreement. For the avoidance
of doubt, all of the Commitment Fee shall be fully earned as of the date of this Agreement,


 




    -25-


     


    

whether
or not the Commencement shall occur or any Purchase Shares are purchased by the Investor under this Agreement and irrespective
of any subsequent termination of this Agreement.


 


(f)       Due
Diligence; Non-Public Information. The Investor shall have the right, from time to time as the Investor may reasonably deem
appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company and its officers and
employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the
Investor related to the Investor's due diligence of the Company. Each party hereto agrees not to disclose any Confidential Information
of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection
with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the Confidential Information
shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy
of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person acting
on its behalf shall provide the Investor or its agents or counsel with any information that constitutes or may constitute or be
deemed to constitute material, non-public information, unless a simultaneous public announcement thereof is made by the Company
in a manner such that upon such public announcement, such information shall not constitute or be deemed to constitute material,
non-public information. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as
determined in the reasonable good faith judgment of the Investor after consulting with U.S. securities counsel), in addition to
any other remedy provided herein or in the other Transaction Documents, if the Investor or any of its affiliates owns or holds,
directly or indirectly, any Purchase Shares at the time of the disclosure of material, non-public information, the Investor shall
have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material,
non-public information without the prior approval by the Company; provided the Investor shall have first provided notice to the
Company that it believes it has received information that constitutes material, non-public information, the Company shall have
at least 24 hours to publicly disclose such material, non-public information prior to any such disclosure by the Investor, and
the Company shall have failed to publicly disclose such material, non-public information within such time period. Neither the
Investor, nor any of its affiliates, shareholders, members, officers, directors, employees and direct or indirect investors, nor
and any of the foregoing Person's agents or other representatives (including, without limitation, those retained in connection
with the transactions contemplated by this Agreement), shall have any liability to the Company, any of its Subsidiaries, or any
of their respective directors, officers, employees, shareholders or agents, for any such public disclosure. The Company understands
and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of the Company.


 


(g)
       Purchase Records. The Investor and the Company shall each maintain records showing
the remaining Available Amount at any given time and the dates and Purchase Amounts for each Regular Purchase and Additional Purchase
or shall use such other method, reasonably satisfactory to the Investor and the Company.


 


(h)
       Taxes.
The Company shall pay, and will indemnify and hold harmless the Investor and all of its affiliates, shareholders, members,
officers, directors, employees and direct or indirect investors for, any and all documentary, stamp, issue, transfer or similar
tax (but not, for the avoidance of doubt, any income or value-added or capital gains tax) including interest and penalties, that
may be payable with respect to the execution and delivery of this Agreement or the creation, issue, sale and delivery of the Purchase
Shares to the Investor pursuant to this Agreement.


 


(i)       Use
of Proceeds. The Company will use the net proceeds from the offering as described in the Registration Statement or the SEC
Documents.


 




    -26-


     


    

(j)       Other
Transactions. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement
or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right
of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the
Company to deliver the Purchase Shares to the Investor in accordance with the terms of the Transaction Documents.


 


(k)       Integration.
From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its
reasonable best efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales
of any security or solicit any offers to buy any security, under circumstances that would cause this offering of the Purchase
Shares to be “integrated” (within the meaning of the Securities Act) with any other offering by the Company.


 


(l)       Emerging
Growth Company Status. For as long as the Investor or any of its affiliates beneficially owns or holds, directly or indirectly,
any Purchase Shares, the Company will promptly notify the Investor if the Company ceases to be an Emerging Growth Company.


 


(m)       Foreign
Private Issuer. For as long as the Investor or any of its affiliates beneficially owns or holds, directly or indirectly, any
Purchase Shares, the Company will provide a written notice to the Investor immediately upon becoming aware that the Company is
no longer a Foreign Private Issuer.


 


(n)       Transfer
Agent. For as long as the Investor or any of its affiliates beneficially owns or holds, directly or indirectly, any Purchase
Shares, the Company agrees to maintain a transfer agent and, if necessary under the jurisdiction of incorporation of the Company,
a registrar for the Common Shares.


 


(o)       Limitation
on Variable Rate Transactions. From and after the date of this Agreement until the later of: (i) the 30-month anniversary
of the date of this Agreement and (ii) the 30-month anniversary of the Commencement Date (if the Commencement has occurred), in
either case irrespective of any earlier termination of this Agreement, the Company and its Subsidiaries shall be prohibited from
effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Shares or Common
Share Equivalents (or any combination of units thereof) in any “equity line of credit”, “at-the-market offering”
or other continuous offering or similar offering in which the Company may offer, issue or sell Common Shares or Common Share Equivalents
(or any combination of units thereof) at a future determined price, other than in connection with an Exempt Issuance. The Investor
shall be entitled to seek injunctive relief against the Company and its Subsidiaries to preclude any such issuance, which remedy
shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other
security being required. “Common Share Equivalents” means any securities of the Company or its Subsidiaries
which entitle the holder thereof to acquire at any time Common Shares, including, without limitation, any debt, preferred stock,
rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Shares. “Exempt Issuance” means the issuance of (a) any Purchase
Shares issued to the Investor pursuant to this Agreement, (b) any securities issued upon the exercise or exchange of or conversion
of any Common Shares or Common Share Equivalents owned or held, directly or indirectly, by the Investor at any time, (c) any securities,
including, without limitation, Common Shares or Common Share Equivalents (or any combination of units thereof), issuable to the
Investor or any of its affiliates or designees pursuant to any other agreement or arrangement between the Investor or any of its
affiliates or designees, on the one hand, and the Company or any of its Subsidiaries, on the other hand, entered into after the
date of this Agreement, if any, or (d) Common Shares issued pursuant to an “at-the-market offering” by the Company
exclusively through a registered broker-dealer acting as agent of the Company pursuant to a written agreement between the Company
and such registered broker-dealer only.


 




    -27-


     


    

6.       TRANSFER
AGENT INSTRUCTIONS.


 


On
the Commencement Date, the Company shall issue to the Transfer Agent, and any subsequent transfer agent, (i) irrevocable instructions
in the form substantially similar to those used by the Investor in substantially similar transactions (the “Commencement
Irrevocable Transfer Agent Instructions”) and (ii) the notice of effectiveness of the Registration Statement in the
form attached as an exhibit to the Registration Rights Agreement (the “Notice of Effectiveness of Registration Statement”),
in each case to issue the Purchase Shares in accordance with the terms of this Agreement and the Registration Rights Agreement.
All Purchase Shares to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement
shall be issued only as DWAC Shares. The Company represents and warrants to the Investor that, while this Agreement is effective,
except as contemplated in Section 2 hereof, no instruction other than the Commencement Irrevocable Transfer Agent Instructions
and the Notice of Effectiveness of Registration Statement referred to in this Section 6 will be given by the Company to
the Transfer Agent with respect to the Purchase Shares from and after Commencement, and the Purchase Shares covered by the Registration
Statement shall otherwise be freely transferable on the books and records of the Company.


 


		7.	CONDITIONS
                                         TO THE COMPANY'S RIGHT TO COMMENCE



 


ISSUANCES
OF COMMON SHARES.


 


The
right of the Company hereunder to commence issuances of the Purchase Shares on the Commencement Date is subject to the satisfaction
of each of the following conditions:


 


(a) The
Investor shall have executed each of the Transaction Documents and delivered the same to the Company;


 


(b) The
Registration Statement covering the resale of the Purchase Shares shall have been declared effective under the Securities Act
by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC; and 


 


(c) The
representations and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as
of the Commencement Date as though made at that time.


 


		8.	CONDITIONS
                                         TO THE INVESTOR'S OBLIGATION TO SUBSCRIBE FOR COMMON SHARES.



 


The
obligation of the Investor to subscribe for the Purchase Shares under this Agreement is subject to the satisfaction of each of
the following conditions on or prior to the Commencement Date and, once such conditions have been initially satisfied, there shall
not be any ongoing obligation to satisfy such conditions after the Commencement has occurred:


 


(a)       The
Company shall have executed each of the Transaction Documents and delivered the same to the Investor;


 


(b)       The
Company shall have paid the Commitment Fee in full to the Investor in accordance with Section 5(e);


 


(c)       The
Common Shares shall be listed or quoted on the Principal Market, trading in the Common Shares shall not have been within the last
365 days suspended by the SEC or the Principal Market, and all Purchase Shares to be issued by the Company to the Investor pursuant
to this Agreement


 




    -28-


     


    

shall
have been approved for listing or quotation on the Principal Market in accordance with the applicable rules and regulations of
the Principal Market, subject only to official notice of issuance;


 


(d)       The
Investor shall have received the opinion and negative assurance of the Company's U.S. legal counsel and the opinion of the Company’s
Swiss legal counsel, each dated as of the Commencement Date substantially in the form heretofore agreed by the parties hereto;


 


(e)       The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any
of such representations and warranties is already qualified as to materiality in Section 4 above, in which case, the portion of
such representations and warranties so qualified shall be true and correct without further qualification) as of the date hereof
and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific
date, which shall be true and correct as of such date) and the Company shall have performed, satisfied and complied with the covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at
or prior to the Commencement Date.


 


(f)       The
Board shall have passed all of the resolutions, duly approved all matters and taken all other actions required by Section 2
to have been passed, approved or effected by the Board on or prior to the Commencement Date, all of which resolutions, approvals
and actions shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date;


 


(g)       The
Investor shall have received a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement
Date, to the effect set forth in Section 8(e) and further to the effect that for the period from and including the date
of this Agreement through and including the Commencement Date, there has not occurred any Material Adverse Change;


 


(h)       The
Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement each shall have
been delivered to and acknowledged in writing by the Company and the Company's Transfer Agent (or any successor transfer agent);


 


(i)       The
Registration Statement covering the resale of the Purchase Shares shall have been declared effective under the Securities Act
by the SEC, and no stop order with respect to the Registration Statement shall be pending or threatened by the SEC. The Company
shall have prepared and filed with the SEC, not later than one (1) Business Day after the effective date of the Registration Statement,
a final and complete prospectus (the preliminary form of which shall be included in the Registration Statement) and shall have
delivered to the Investor a true and complete copy thereof. Such prospectus shall be current and available for the resale by the
Investor of all of the Purchase Shares covered thereby. The Current Report shall have been filed with the SEC, as required pursuant
to Section 5(a). All reports, schedules, registrations, forms, statements, information and other documents required to
have been filed by the Company with the SEC at or prior to the Commencement Date pursuant to the reporting requirements of the
Exchange Act shall have been filed with the SEC within the applicable time periods prescribed for such filings under the Exchange
Act;


 


(m)       No
Event of Default has occurred, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred;


 


(n)       All
federal, state and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction
Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents,


 




    -29-


     


    

authorizations
and orders of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal,
state and local regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction
Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained
or made, including, without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state
securities or “Blue Sky” laws or applicable rules and regulations of the Principal Market, or otherwise required by
the SEC, the Principal Market or any state securities regulators;


 


(o)       No
statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
by any federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation
of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents; and


 


(p)       No
action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent
jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign
governmental authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers,
directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction
Documents, or seeking material damages in connection with such transactions.


 


		9.	INDEMNIFICATION.
                                         



 


In
consideration of the Investor's execution and delivery of the Transaction Documents and acquiring the Purchase Shares hereunder
and in addition to all of the Company's other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless the Investor and all of its affiliates, stockholders, officers, directors, employees and direct or
indirect investors (collectively, the "Indemnitees") from and against any and all actions, causes of action,
suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of
whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including documented
and reasonably incurred attorneys' fees and disbursements (the "Indemnified Liabilities"), incurred by any Indemnitee
as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by
the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b)
any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, or (c) any cause of action, suit or claim brought or made against such
Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction Documents
or any other certificate, instrument or document contemplated hereby or thereby, other than, in the case of clause (c), with respect
to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful misconduct of an Indemnitee.
The indemnity in this Section 9 shall not apply to amounts paid in settlement of any claim if such settlement is effected without
the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. To the extent
that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Payment under
this indemnification shall be made within thirty (30) days from the date Investor makes written request for it. A certificate
containing reasonable detail as to the amount of such indemnification submitted to the Company by Investor shall be conclusive
evidence, absent manifest error, of the amount due from the Company to Investor. If any action shall be brought against any Indemnitee
in respect of which indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly notify the Company in writing,
and the Company shall have the right to


 




    -30-


     


    

assume
the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any Indemnitee shall have the right
to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Indemnitee, except to the extent that (i) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable written opinion of such separate counsel, delivered to the Company,
a material conflict on any material issue between the position of the Company and the position of such Indemnitee, in which case
the Company shall be responsible for the documented and reasonably incurred fees and expenses of no more than one such separate
counsel.


 


10.       EVENTS
OF DEFAULT. 


 


An
"Event of Default" shall be deemed to have occurred at any time as any of the following events occurs:


 


(a)       the
effectiveness of a registration statement registering the resale of the Purchase Shares lapses for any reason (including, without
limitation, the issuance of a stop order or similar order) or such registration statement (or the prospectus forming a part thereof)
is unavailable to the Investor for resale of any or all of the Purchase Shares to be issued to the Investor under the Transaction
Documents, and such lapse or unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate
of thirty (30) Business Days in any 365-day period, but excluding a lapse or unavailability where (i) the Company terminates a
registration statement after the Investor has confirmed in writing that all of the Purchase Shares covered thereby have been resold
or (ii) the Company supersedes one registration statement with another registration statement, including (without limitation)
by terminating a prior registration statement when it is effectively replaced with a new registration statement covering Purchase
Shares (provided in the case of this clause (ii) that all of the Purchase Shares covered by the superseded (or terminated) registration
statement that have not theretofore been resold are included in the superseding (or new) registration statement);


 


(b)       the
suspension of the Common Shares from trading on the Principal Market for a period of one (1) Business Day, provided that the Company
may not direct the Investor to purchase any shares of Common shares during any such suspension;


 


(c)       the
delisting of the Common shares from The NASDAQ Capital Market, provided, however, that the Common Shares are not immediately thereafter
trading on the New York Stock Exchange, The NASDAQ Global Market, The NASDAQ Global Select Market, the NYSE American, the NYSE
Arca, the OTC Bulletin Board or OTC Markets (or nationally recognized successor to any of the foregoing);


 


(d)       the
failure for any reason by the Transfer Agent to issue Purchase Shares to the Investor within three (3) Business Days after the
applicable Purchase Date on which the Investor is entitled to receive such Purchase Shares;


 


(e)       the
Company breaches any representation, warranty, covenant or other term or condition under any Transaction Document if such breach
would reasonably be expected to have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably
curable, only if such breach continues for a period of at least five (5) consecutive Business Days;


 


(f)       if
any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;


 




    -31-


     


    

(g)       if
the Company, pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case, (ii) consents to the entry
of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or
substantially all of its property, or (iv) makes a general assignment for the benefit of its creditors or is generally unable
to pay its debts as the same become due;


 


(h)       a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company
in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its property, or (iii) orders
the liquidation of the Company or any Subsidiary; or


 


(i)       if
at any time the Company is not eligible to transfer its Common Shares electronically as DWAC Shares.


 


In addition
to any other rights and remedies under applicable law and this Agreement, so long as an Event of Default has occurred and is continuing,
or if any event which, after notice and/or lapse of time, would become an Event of Default, has occurred and is continuing, the
Company shall not deliver to the Investor any Regular Purchase Notice or Additional Purchase Notice.


 


11.       TERMINATION


 


This
Agreement may be terminated only as follows:


 


(a)       If
pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company
makes a general assignment for the benefit of its creditors (any of which would be an Event of Default as described in Sections
10(f), 10(g) and 10(h) hereof), this Agreement shall automatically terminate without any liability or payment
to the Company (except as set forth below) without further action or notice by any Person.


 


(b)       In
the event that (i) the Company fails to file the Registration Statement with the SEC within the period specified in Section
5(a) hereof in accordance with the terms of the Registration Rights Agreement or (ii) the Commencement shall not have occurred
on or before August 31, 2018, due to the failure to satisfy the conditions set forth in Sections 7 and 8 above with
respect to the Commencement, then, in the case of clause (i) above, this Agreement may be terminated by the Investor at any time
prior to the filing of the Registration Statement and, in the case of clause (ii) above, this Agreement may be terminated by either
party at the close of business on August 31, 2018 or thereafter, in each case without liability of such party to the other party
(except as set forth below); provided, however, that the right to terminate this Agreement under this Section 11(b) shall
not be available to any party if such party is then in breach of any covenant or agreement contained in this Agreement or any
representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions set
forth in Section 7(c) or Section 8(e), as applicable, could not then be satisfied.


 


(c)       
At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no
reason by delivering notice (a “Company Termination Notice”) to the Investor electing to terminate this Agreement
without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). The Company
Termination Notice shall not be effective until one (1) Business Day after it has been received by the Investor.


 


(d)       This
Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount
as provided herein, without any action or notice on the part


 




    -32-


     


    

of
any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).


 


(e)       If,
for any reason or for no reason, the full Available Amount has not been purchased in accordance with Section 2 of
this Agreement by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or
notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except
as set forth below).


 


Except as
set forth in Sections 11(a) (in respect of an Event of Default under Sections 10(f), 10(g) and 10(h)), 11(d)
and 11(e), any termination of this Agreement pursuant to this Section 11 shall be effected by written notice
from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination
hereof. The representations and warranties and covenants of the Company and the Investor contained in Sections 3, 4,
5, and 6 hereof, the indemnification provisions set forth in Section 9 hereof and the agreements and covenants
set forth in Sections 2 (c) –(i) (in the event of any then pending Regular Purchase Notice and/or Additional Purchase
Notice and/or any Capital Increase Amount or any other funds are then remaining in any bank account pursuant to Section 2 hereof),
10, 11 and 12 shall survive the execution and delivery of this Agreement and any termination of this Agreement.
No termination of this Agreement shall (i) affect the Company’s or the Investor’s rights or obligations under (A)
this Agreement with respect to any pending Regular Purchase Notice and/or Additional Purchase Notice (including, without limitation,
with respect to any Capital Increase Amount or any other funds then on deposit in any bank account pursuant to Section 2 hereof
or any other actions taken in connection with such pending purchase), that has been properly and timely delivered by the Company
to the Investor pursuant to and in accordance with this Agreement but settlement thereof has not then been completed, and the
Company and the Investor shall complete their respective obligations with respect to any Regular Purchase Notice and/or Additional
Purchase Notice that has been properly and timely delivered by the Company to the Investor pursuant to and in accordance with
this Agreement, which purchases shall be settled in accordance with this Agreement, and (B) the Registration Rights Agreement,
which shall survive any such termination of this Agreement and continue until the expiration of the term of the Registration Rights
Agreement as provided therein, or (ii) be deemed to release the Company or the Investor from any liability for intentional misrepresentation
or willful breach of any of the Transaction Documents.


 


12.       MISCELLANEOUS.


 


(a)       Governing
Law Provisions; Currency Provisions. This Agreement shall be governed by and construed in accordance with the internal
laws of the State of New York applicable to agreements made and to be performed in such state, without giving effect to any
choice of law or conflict of law provision or rule. Any legal suit, action or proceeding arising out of or based upon the
Purchase Shares, this Agreement or any of the other Transaction Documents or any of the transactions contemplated hereby or
thereby (“Related Proceedings”) may be instituted in any of the federal courts of the United States of
America or any of the courts of the State of New York, in each case located in the State of New York, Borough of Manhattan,
in the City of New York, New York, U.S.A. (collectively, the “Specified Courts”), and each party
irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a
judgment of any such court (a “Related Judgment”), as to which such jurisdiction is non-exclusive) of any
of the Specified Courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail
to such party’s address set forth  in Section 12(f) to this Agreement shall be effective service of process for any
suit, action or other proceeding brought in any of the Specified Courts. The parties irrevocably and unconditionally waive
any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably
and unconditionally waive and agree not to plead or claim in any of the Specified Courts that any such suit, action or
other proceeding brought in any of the Specified Courts has been brought in an inconvenient forum. EACH 


 




    -33-


     


    

PARTY
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER
OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. The Company has irrevocably
appointed Auris Medical Inc., which currently maintains an office at 500 North Michigan Avenue, Suite 600, Chicago Illinois 60611,
United States of America, as its agent to receive service of process or other legal summons for purposes of any such suit, action
or proceeding that may be instituted in any of the Specified Courts.


 


With
respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity
(whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment)
and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each
party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim
or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without
limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.


 


The
obligations of the Company pursuant to this Agreement in respect of any sum due to the Investor shall, notwithstanding any judgment
in a currency other than United States dollars, not be discharged until the first business day, following receipt by the Investor
of any sum adjudged to be so due in such other currency, on which the Investor may in accordance with normal banking procedures
purchase United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally
due to the Investor in United States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such
judgment, to indemnify the Investor against such loss. If the United States dollars so purchased are greater than the sum originally
due to the Investor hereunder, the Investor agrees to pay to the Company an amount equal to the excess of the dollars so purchased
over the sum originally due to the Investor hereunder. Unless otherwise expressly indicated, all dollar amounts referred to in
this Agreement and the other Transaction Documents are in United States Dollars (“U.S. Dollars”), and all amounts
owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in other
currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date
of calculation.


 


All
payments made by the Company under this Agreement, if any, will be made without withholding or deduction for or on account of
any present or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed
or levied by or on behalf of Switzerland, any other jurisdiction from or through which payment is made, or, in each case, any
political subdivision or any taxing authority thereof or therein unless the Company is or becomes required by law to withhold
or deduct such taxes, duties, assessments or other governmental charges. In such event, the Company will pay such additional amounts
as will result, after such withholding or deduction, in the receipt by the Investor and each person controlling the Investor,
as the case may be, of the amounts that would otherwise have been receivable in respect thereof


 


(b)       Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a
facsimile signature or signature delivered by e-mail in a “.pdf” format data file shall be considered due execution
and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.


 


(c)       Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.


 




    -34-


     


    

(d)       Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.


 


(e)       Entire
Agreement. The Transaction Documents supersede all other prior oral or written agreements between the Investor, the Company,
their affiliates and Persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other
Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the
matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor
makes any representation, warranty, covenant or undertaking with respect to such matters. The Company acknowledges and agrees
that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly
set forth in the Transaction Documents.


 


(f)       Notices.
Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile
or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
to the party to receive the same. The addresses for such communications shall be:


 


 


 





	If
    to the Company:	 	 
	Auris Medical
    Holding AG	 
	Bahnhofstrasse
    21	 
	6300 Zug,
    Switzerland	 
	Telephone:	[****]	 
	Facsimile:	[****]	 
	Attention:  	Thomas Meyer, Chairman & CEO	 
	 	 	 
	With
    a copy to (which shall not constitute notice or service of process):
	Davis
    Polk & Wardwell LLP	 
	450
    Lexington Avenue	 
	New
    York, New York 10017	 
	Telephone:	[****]	 
	Facsimile:	[****]	 
	E-mail:	[****]	 
	Attention:	Sophia
    Hudson, Esq.	 
	 	 	 
	If
    to the Investor:	 	 
	Lincoln
    Park Capital Fund, LLC	 
	440
    North Wells, Suite 410	 
	Chicago,
    IL 60654	 
	Telephone:	[****]	 
	Facsimile:	[****]	 
	E-mail:	[****]	 
	Attention:	Josh
    Scheinfeld/Jonathan Cope	 
	 	 	 
	With
    a copy to (which shall not constitute notice or service of process):



 


 






    -35-


     


    

 











	Mintz,
    Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	666
    Third Avenue	 
	New
    York, NY 10017	 
	Telephone:	[****]	 
	Facsimile:
    	[****]	 
	E-mail:	[****]	 
	Attention:	Anthony J. Marsico,
    Esq.	 
	 	 	 
	If to
    the Transfer Agent:	 
	American
    Stock Transfer & Trust Company, LLC	 
	6201
    15th Avenue	 
	Brooklyn,
    New York 11219	 
	Telephone:	[****]	 
	Attention:
    	Susan Silber	 


 


or at such
other address and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written
notice given to each other party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt
(A) given by the recipient of such notice, consent or other communication, (B) mechanically or electronically generated by the
sender's facsimile machine or email account containing the time, date, and recipient facsimile number or email address, as applicable,
and an image of the first page of such transmission or (C) provided by a nationally recognized overnight delivery service, shall
be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service
in accordance with clause (i), (ii) or (iii) above, respectively.


 


(g)       Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and any permitted successors and
assigns of the Company. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Investor, including by merger or consolidation. The Investor may not assign its rights or obligations under this
Agreement.


 


(h)       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and any permitted successors and
assigns of the Company and, except as set forth in Section 9, is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.


 


(i)       Publicity.
The Company shall afford the Investor and its counsel with the opportunity to review and comment upon the form and substance of,
and shall give reasonable consideration to all such comments from the Investor or its counsel on, any press release, SEC filing
or any other public disclosure by or on behalf of the Company relating to the Investor, its purchases hereunder or any aspect
of the Purchase Shares, the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to the
issuance, filing or public disclosure thereof. The Investor must be provided with a final version of any such press release, SEC
filing or other public disclosure at least 24 hours prior to any release, filing or use by the Company thereof. The Company agrees
and acknowledges that its failure to fully comply with this provision constitutes a Material Adverse Effect.


 


(j)       Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to consummate and make effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish
the purposes of this Agreement and the consummation of the transactions contemplated hereby.


 




    -36-


     


    

(k)       No
Financial Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to the Investor that it has not
engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The
Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder
in connection with the transactions contemplated hereby. The Company shall be responsible for the payment of any fees or commissions,
if any, of any financial advisor, placement agent, broker or finder relating to or arising out of the transactions contemplated
hereby. The Company shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation,
attorneys' fees and out of pocket expenses) arising in connection with any such claim.


 


(l)       No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.


 


(m)       Remedies,
Other Obligations, Breaches and Injunctive Relief. The parties’ remedies provided in this Agreement, including, without
limitation, the parties’ remedies provided in Section 9, shall be cumulative and in addition to all other remedies
available to the parties under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive
relief), no remedy of any party contained herein shall be deemed a waiver of compliance with the provisions giving rise to such
remedy and nothing herein shall limit the parties’ right to pursue actual damages for any failure by either party to comply
with the terms of this Agreement. Each party acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the other party and that the remedy at law for any such breach may be inadequate. Each party therefore agrees that, in
the event of any such breach or threatened breach, the other party shall be entitled, in addition to all other available remedies,
to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security
being required.


 


(n)       Enforcement
Costs. If: (i) this Agreement or any other Transaction Document is placed by the Investor in the hands of an attorney for
enforcement or is enforced by the Investor through any legal proceeding; (ii) an attorney is retained to represent the Investor
in any bankruptcy, reorganization, receivership or other proceedings affecting creditors' rights and involving a claim under this
Agreement or any other Transaction Document; or (iii) an attorney is retained to represent the Investor in any other proceedings
whatsoever in connection with this Agreement or any other Transaction Document, then the Company shall pay to the Investor, as
incurred by the Investor, all reasonable costs and expenses including attorneys' fees incurred in connection therewith, in addition
to all other amounts due hereunder. If this Agreement is placed by the Company in the hands of an attorney for enforcement or
is enforced by the Company through any legal proceeding, then the Investor shall pay to the Company, as incurred by the Company,
all reasonable, actual and documented costs and expenses including reasonable attorneys’ fees incurred in connection therewith,
in addition to all other amounts due hereunder. It is understood and agreed that any and all enforcement costs paid by a party
to the other party pursuant to this section shall be promptly reimbursed by the receiving party if a court of competent jurisdiction
determines in a final, non-appealable order that the paying party is not in breach of this Agreement.


 


(o)       Amendment
and Waiver; Failure or Indulgence Not Waiver. No provision of this Agreement may be amended or waived by the parties from
and after the date that is one (1) Business Day immediately preceding the initial filing of the Registration Statement with the
SEC. Subject to the immediately preceding sentence, (i) no provision of this Agreement may be amended other than by a written
instrument signed by both parties hereto and (ii) no provision of this Agreement may be waived other than in a written instrument
signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right
or privilege hereunder shall operate as a waiver


 




    -37-


     


    

thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of
any other right, power or privilege.


 


*
* * * *


 




    -38-


     


    

IN WITNESS
WHEREOF, the Investor and the Company have caused this Agreement to be duly executed as of the date first written above.


 


 


 








	 	THE COMPANY:
	 	 	 
	 	AURIS MEDICAL HOLDING AG
	 	 	 
	 	By:	/s/ Thomas Meyer
	 	Name:	Thomas Meyer
	 	Title:

	Chairman & CEO
	 	 	 
	 	 	 
	 	INVESTOR:
	 	 	 
	 	LINCOLN PARK CAPITAL FUND, LLC
	 	BY: LINCOLN PARK CAPITAL, LLC
	 	BY: ROCKLEDGE CAPITAL CORPORATION
	 	 	 
	 	By:	 /s/ Josh Scheinfeld
	 	Name: 	Josh Scheinfeld
	 	Title: 	President



 





 





 





 





 





 





 





 





 




    -39-


     


    

EXHIBITS


 





	Exhibit A	Subscription Form
	 	 
	 	 
	 	 
	 	 



 


 





 




     


     


    

EXHIBIT
A


 


SUBSCRIPTION
FORM


 


Zeichnungsschein





Subscription
Form


 





 






 


Die Unterzeichnende





The undersigned 


 


Lincoln Park Capital Fund
LLC, 440 N. Wells Street, Suite 410, Chicago, IL 60654, USA,


 


handelnd im eigenen Namen,



acting in its own name,


 


hat Kenntnis
genommen:


 


takes
note of:


 


(i) von
den Statuten von Auris Medical Holding AG, Zug (die Gesellschaft) vom 30. Januar 2018, (ii) vom Generalversammlungsbeschluss
der Gesellschaft vom 30. Januar 2018 betreffend die Ermächtigung des Verwaltungsrates der Gesellschaft, das Aktienkapital
jederzeit bis zum 29. Januar 2020 im Maximalbetrag von CHF 61‘000.00 durch Ausgabe von höchstens 3‘050‘000
vollständig zu liberierenden Namenaktien mit einem Nennwert von je CHF 0.02 zu erhöhen, und (iii) vom Beschluss des
Verwaltungsrates der Gesellschaft vom [Datum] 2018, wonach gestützt auf Artikel 3a der Statuten über das genehmigte
Kapital beschlossen wurde, das Aktienkapital in einem oder mehreren Schritten von CHF 122‘347.76 um maximal CHF 61‘000.00
auf maximal CHF 183‘347.76 durch Ausgabe von maximal 3'050'000 neuen Aktien mit einem Nominalwert von CHF 0.02 pro
Aktie zu erhöhen, zu einem Ausgabebetrag von CHF 0.02 bzw. einem Preis (d.h. inkl. Agio) von CHF [Betrag] pro Aktie,
d.h. insgesamt um maximal CHF 61‘000.00 (bzw. einem Gesamtausgabepreis von total CHF [Betrag]);


 


(i) the
articles of association of Auris Medical Holding AG, Zug (the Company) dated January 30, 2018, (ii) the resolution of the
general meeting of shareholders of the Company dated January 30, 2018, authorizing the Board of Directors of the Company to increase,
at any time until January 29, 2020, by a maximum amount of CHF 61,000.00 by issuing a maximum of 3’050’000 fully
paid-up registered shares with a par value of CHF 0.02 each, and (iii) the resolution of the Board of Directors of the Company
dated [date] 2018, pursuant to which the share capital is to be increased, in one or in more steps, from CHF 122‘347.76
by a maximum amount of CHF 61,000.00 to a maximum amount of CHF 183,347.76 through the issuance of a maximum amount
of 3,050,000 new registered shares with a par value of CHF 0.02 each, at the issue amount of CHF 0.02 per share (i.e. at an price
incl. surplus (agio) of CHF [amount] per shares), i.e., for an aggregate issue amount of up to CHF 61,000.00 (and total price
of CHF [amount]);


 




     


     


    

und / and


 


		1	zeichnet
                                         hiermit [Anzahl] neue Namenaktien zum Nominalwert von je CHF 0.02; und 



 




hereby subscribes for [number] new registered shares with a par value of CHF 0.02 each; and






 


		2	verpflichtet
                                         sich hiermit bedingungslos, auf jede gezeichnete Aktie (i) eine Einlage von CHF 0.02,
                                         insgesamt somit CHF [Betrag], zu leisten auf das Kapitaleinzahlungskonto bei der
                                         UBS Switzerland AG, Bärenplatz 8, Postfach, 3011 Bern (Kontonummer [Details]; Konto
                                         lautend auf: AURIS MEDICAL HOLDING AG KAPITALERHÖHUNG), sowie, soweit nicht bereits
                                         erfolgt (ii) Agio im Gesamtbetrag von CHF [Betrag] auf das Gesellschafts-Konto bei
                                         der UBS Switzerland AG, Bärenplatz 8, Postfach, 3011 Bern (Kontonummer [Details];
                                         Konto lautend auf: [Name]),



 


herewith
unconditionally undertakes to pay-in the (i) contribution of CHF 0.02 for each subscribed share, thus in total CHF [amount],
to the capital increase account with UBS Switzerland AG, Bärenplatz 8, P.O. Box, 3011 Berne (bank account number [number];
account in the name of: AURIS MEDICAL HOLDING AG KAPITALERHÖHUNG), and, unless already effected (ii) the capital surplus
(agio) in the total amount of CHF [amount] to the company account with UBS Switzerland AG, Bärenplatz 8, P.O. Box, 3011 Berne
(bank account number [number]; account in the name of: [name]).


 




Dieser Zeichnungsschein ist gültig bis zum [Datum].


 


This
subscription form is valid until [date]. 


 


[Unterschriften
auf der nächsten Seite]


 


[Signatures
on next page]


 


 


 


 


 


 


 


 


 


 


 




     


     


    

 


[Place],
_____________________ 2018


 


Lincoln Park Capital Fund
LLC


 








 


	Name:
    	 	Name: